MoonLake Immunotherapeutics reports on week 16 results of the VELA Phase 3 hidradenitis suppurativa program with the Nanobody® sonelokimab

VELA-1 and VELA-2 are two identical trials to evaluate the efficacy and safety of sonelokimab in adult participants with moderate to severe ...
The BMJ

We need greater awareness of the ADHD continuum

Recognising that ADHD exists on a continuum could help reduce misunderstanding and improve interventions, writes Jonna Kuntsi The debate around attention deficit/hyperactivity disorder (ADHD), in the ...
pv magazine Australia

New algorithms boost dual-axis solar tracker performance

Researchers in Australia and India have developed two solar tracker optimisation techniques that can purportedly increase ...
EuropaWire

Cosentyx Becomes First Novartis Medicine Offered at 55% Discount Through New DTP Model

Novartis will launch a direct-to-patient (DTP) platform in the US on November 1, 2025, starting with Cosentyx, which will be offered at a 55% dis ...